Parallel Advisors’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Parallel Advisors’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-67,738	Closed	-$19.7K	–	3511
2024 Q2	$19.7K	Hold	67,738	–	–	﹤0.01%	1994
2024 Q1	$975K	Sell	67,738 -4	-0%	-$48	0.03%	369
2023 Q4	$792K	Hold	67,742	–	–	0.02%	383
2023 Q3	$1.02M	Hold	67,742	–	–	0.03%	309
2023 Q2	$1.41M	Hold	67,742	–	–	0.05%	258
2023 Q1	$597K	Hold	67,742	–	–	0.02%	410
2022 Q4	$724K	Hold	67,742	–	–	0.03%	322
2022 Q3	$969K	Hold	67,742	–	–	0.04%	244
2022 Q2	$2.4M	Buy	67,742 +40,644	+150%	+$2.46M	0.11%	128
2022 Q1	$2.74M	Buy	+27,098	New	+$3.6M	0.11%	130
2021 Q3	–	Sell	-10	Closed	-$2K	–	3316
2021 Q2	$2K	Buy	+10	New	+$2.46K	﹤0.01%	2642

Other funds holding EFTR

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Parallel Advisors's EFTR Position: Q3 2024 in Review

Parallel Advisors sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2024, closing a stake of 67,738 shares — an estimated $19.7K sold.

Parallel Advisors first reported a position in EFTR in Q2 2021 and held it in 11 quarters. The position peaked at $2.74M in Q1 2022. 3 funds tracked by Wall St. Rank hold EFTR as of Q3 2024.

Parallel Advisors reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Parallel Advisors sold 67,738 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $19.7K.
Parallel Advisors first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
Parallel Advisors's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $2.74M in Q1 2022.
3 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Parallel Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.